Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gridelli

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
ESMO Open|March 7, 2024
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trialsL Arenare, R Di Liello, P De Placido, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2015
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)J Vansteenkiste, F Barlesi, C F Waller, et al.
British Journal of Cancer|November 24, 2004
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 studyC Gridelli, C Gallo, M Di Maio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)H J M Groen, M A Socinski, F Grossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996
Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.)C Gridelli, F Perrone, S Palmeri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer ProjectL Crinò, G V Scagliotti, S Ricci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
British Journal of Cancer|May 27, 2004
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancerM Di Maio, C Gridelli, C Gallo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
British Journal of Cancer|September 11, 2003
Supportive care in patients with advanced non-small-cell lung cancerM Di Maio, F Perrone, C Gallo, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
ESMO Open|March 7, 2024
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trialsL Arenare, R Di Liello, P De Placido, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2015
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)J Vansteenkiste, F Barlesi, C F Waller, et al.
British Journal of Cancer|November 24, 2004
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 studyC Gridelli, C Gallo, M Di Maio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)H J M Groen, M A Socinski, F Grossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996
Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.)C Gridelli, F Perrone, S Palmeri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer ProjectL Crinò, G V Scagliotti, S Ricci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
British Journal of Cancer|May 27, 2004
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancerM Di Maio, C Gridelli, C Gallo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
British Journal of Cancer|September 11, 2003
Supportive care in patients with advanced non-small-cell lung cancerM Di Maio, F Perrone, C Gallo, et al.
Pageof 11